Core Viewpoint - Huaxi Biological Technology Co., Ltd. announced a settlement regarding arbitration with Medytox Inc., leading to the termination of the arbitration process and the planned dissolution of their joint venture, Medybloom Limited, with an expected positive financial impact from asset recovery [1][2][3] Group 1: Arbitration Background and Settlement Progress - The joint venture, Medybloom Limited, was established in May 2015, with both parties holding 50% stakes, focusing on the development and sales of Medytox's medical aesthetic products in mainland China [2] - Due to the inability to achieve the cooperation objectives, Gentix Limited initiated arbitration in January 2023 [2] - The settlement agreement stipulates the termination of arbitration by October 29, 2025, with all related claims withdrawn within ten days of signing [2] Group 2: Joint Venture Dissolution and Financial Impact - Medybloom Limited will be dissolved after the distribution of remaining assets, with Huaxi Biological expecting to recover approximately 9.6 million Hong Kong dollars, positively affecting current profits [3] - The company had previously fully impaired its long-term equity investment in Medybloom by the end of 2023 [3] - The settlement is seen as beneficial for maintaining a cooperative relationship with Medytox, avoiding additional costs associated with arbitration [3]